Olumiant
Developed to support immune system regulation and to address symptoms of autoimmune conditions.
Strengths: 4mg
Where to Check Availability
Medicine details
- Therapeutic class
Janus Kinase (JAK) Inhibitor
- Pharmacological class
JAK Inhibitor
- Contraindications
hypersensitivity to baricitinib; pregnancy; severe active infections
- Minor side effects
nausea; upper respiratory tract infection
- Moderate side effects
herpes zoster infection; elevated liver enzymes
- Dosage forms
Film-coated tablet
- Administration route
Oral use
- Prescription status
POM
- Manufacturer
Eli Lilly
- Onset Time
1–3 hours
- Duration
24 hours
- Storage instructions
Store below 30°C in the original packaging.
- Drug interactions
probenecid; live vaccines
- Age restrictions
Not for children.
- Pregnancy and breastfeeding
Pregnancy: Not recommended. Breastfeeding: Avoid during treatment.
Precautions and warnings
screen for tuberculosis prior to initiation; regular blood monitoring recommended
Serious side effects
venous thromboembolism — requires immediate medical attention; serious infection — requires immediate medical attention
Patient summary
Developed to support immune system regulation and to address symptoms of autoimmune conditions.
Mechanism of action
Baricitinib is a reversible inhibitor of Janus kinases (JAK1 and JAK2). It interrupts the signaling pathways of cytokines involved in inflammatory processes, thereby reducing immune-mediated damage.
Olumiant
Developed to support immune system regulation and to address symptoms of autoimmune conditions.
Editorial Notes
- Active ingredient(s): Baricitinib
- Listed indication(s): Rheumatoid Arthritis, Atopic Dermatitis, Alopecia Areata
Available option
- 7 tablets - 4 mg1304-4-mg-15548